Stay updated with breaking news from Nasdaq Ormp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) from a hold rating to a sell rating in a report published on Monday morning. A number of other research analysts also recently weighed in on ORMP. Canaccord Genuity Group downgraded Oramed Pharmaceuticals from a buy rating to a hold rating and dropped their price […]
Private Portfolio Partners LLC lowered its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) by 20.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 53,600 shares of the biotechnology company’s stock after selling 13,800 shares during the period. Private Portfolio Partners LLC’s holdings in Oramed Pharmaceuticals were worth $645,000 at the end […]
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday. Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald cut Oramed Pharmaceuticals from an “overweight” rating to […]
Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $7.47 and traded as high as $8.29. Oramed Pharmaceuticals shares last traded at $7.96, with a volume of 188,755 shares traded. Analysts Set New Price Targets ORMP […]
Strs Ohio cut its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) by 41.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,400 shares of the biotechnology company’s stock after selling 3,900 shares during the quarter. […]